Read by QxMD icon Read

Journal of Thoracic Oncology

Roberto Ferrara, Laura Mezquita, Benjamin Besse
The treatment paradigm of non-small cell lung cancer (NSCLC) underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival (OS) both in unselected pretreated patients and in untreated patients with PD-L1 expression ≥50%. Furthermore, compelling preliminary results were reported for new combinations of anti-PD-1/PD-L1 agents with chemotherapy or anti-CTLA4 inhibitors. The success of the ICIs appeared to extend to patients with small cell lung cancer (SCLC), mesothelioma or thymic tumors...
January 10, 2018: Journal of Thoracic Oncology
Giorgio V Scagliotti, Dale Shuster, Sergey Orlov, Joachim von Pawel, Frances A Shepherd, Jeffrey S Ross, Qiang Wang, Brian Schwartz, Wallace Akerley
INTRODUCTION: This exploratory subgroup analysis of the MARQUEE study evaluated the efficacy and safety of erlotinib plus tivantinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). METHODS: Patients with advanced, non-squamous, EGFR and mesenchymal-epithelial transition (MET) inhibitor-naive NSCLC, previously treated with 1 to 2 lines of systemic therapy, were randomized to oral erlotinib (150 mg once daily) plus tivantinib (360 mg twice daily) or to erlotinib plus placebo...
December 27, 2017: Journal of Thoracic Oncology
Eric D Miller, James L Fisher, Karl E Haglund, John C Grecula, Meng Xu-Welliver, Erin M Bertino, Kai He, Peter G Shields, David P Carbone, Terence M Williams, Gregory A Otterson, Jose G Bazan
INTRODUCTION: Elderly patients represent the majority of lung cancer diagnoses but are poorly represented in clinical trials. We evaluated the overall survival (OS) of elderly patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiation compared to those treated with definitive chemoradiation. METHODS: We conducted a comparative effectiveness study of radiation therapy vs. chemoradiation in elderly (≥70 years old) patients with stage III NSCLC not treated surgically diagnosed from 2003-2014 using the National Cancer Database...
December 18, 2017: Journal of Thoracic Oncology
Sara Pilotto, Isabella Sperduti, Giovanni Leuzzi, Marco Chiappetta, Felice Mucilli, Giovanni Battista Ratto, Filippo Lococo, Pierluigi Filosso, Lorenzo Spaggiari, Silvia Novello, Michele Milella, Antonio Santo, Aldo Scarpa, Maurizio Infante, Giampaolo Tortora, Francesco Facciolo, Emilio Bria
INTRODUCTION: We developed one of the first clinicopathological prognostic nomograms for resected squamous cell lung cancer (SQLC). Herein, we validate the model in a larger multicenter cohort and we explore the impact of adjuvant/neoadjuvant treatment (ANT). METHODS: Resected SQLC patients from January 2002 to December 2012 in six institutions were eligible. To each patient was assigned a prognostic score based on those clinicopathological factors included in the model (age, T-descriptor according to TNM 7th edition, lymph nodes, grading)...
December 18, 2017: Journal of Thoracic Oncology
Si-Pei Wu, Ri-Qiang Liao, Hai-Yan Tu, Wen-Jun Wang, Zhong-Yi Dong, Shu-Mei Huang, Wei-Bang Guo, Lan-Ying Gou, Hui-Wen Sun, Qi Zhang, Zhi Xie, Li-Xu Yan, Jian Su, Jin-Ji Yang, Wen-Zhao Zhong, Xu-Chao Zhang, Yi-Long Wu
INTRODUCTION: Inhibition of programmed cell death-1 (PD-1) and its ligand PD-L1 using an immune checkpoint inhibitor has emerged as a promising immunotherapy for non-small-cell lung cancer (NSCLC). The correlation of PD-L1 expression in tumor cells with treatment outcomes has been reported in many pivotal trials; however, the relation remains unclear. Here, we demonstrate that the patients with both high density of PD-1+CD8 and PD-L1+CD4+CD25+ (PD-1hiPD-L1hi) regulatory T cells (Tregs) have a better response to PD1/PD-L1 blockade...
December 18, 2017: Journal of Thoracic Oncology
Tyler P Robin, D Ross Camidge, Kelly Stuhr, Sameer K Nath, Robert E Breeze, Jose Pacheco, Arthur K Liu, Laurie E Gaspar, W Thomas Purcell, Robert C Doebele, Brian D Kavanagh, Chad G Rusthoven
INTRODUCTION: Patients with brain metastases (BM) arising from EGFR-mutated and ALK-rearranged NSCLC have a favorable prognosis compared to non-oncogene-addicted NSCLC, emphasizing the importance of minimizing toxicities, such as the cognitive sequelae of whole brain radiation therapy (WBRT). Nevertheless, while radiosurgery without WBRT is the preferred strategy for 1-3 BM, this paradigm remains controversial for patients with multiple BM. METHODS: We reviewed the cases of patients with oncogene-addicted NSCLC presenting to our cancer center between 2008 and 2017 and included only patients treated to ≥4 BM in a single radiosurgery session...
December 18, 2017: Journal of Thoracic Oncology
Enriqueta Felip, Fabrice Barlesi, Benjamin Besse, Quincy Chu, Leena Gandhi, Sang-We Kim, Enric Carcereny, Lecia V Sequist, Paal Brunsvig, Christos Chouaid, Egbert F Smit, Harry J M Groen, Dong-Wan Kim, Keunchil Park, Emin Avsar, Sebastian Szpakowski, Mikhail Akimov, Edward B Garon
INTRODUCTION: In this phase 2 study, we evaluated the activity of AUY922 in pretreated stage IV NSCLC patients. METHODS: Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in EGFR, ALK, KRAS, or wild-type for all three. All patients must have received > 2 prior lines of therapy, except a fifth stratum for less pretreated EGFR cohort (EGFR < 2). In EGFR mutant and ALK-rearranged strata, prior platinum therapy was not required...
December 13, 2017: Journal of Thoracic Oncology
Shisuo Du, Lin Zhou, Gregory S Alexander, Kyewon Park, Lifeng Yang, Nadan Wang, Xinliang Ma, Yajing Wang, Adam P Dicker, Bo Lu
INTRODUCTION: Combined immune checkpoint blockade has led to rare autoimmune complications, such as fatal myocarditis. Recent approvals of several anti-PD1 drugs for lung cancer treatment prompted ongoing clinical trials that directly combine PD-1 inhibitors with thoracic radiotherapy for locally advanced lung cancer. Overlapping toxicities from either modality have the potential to increase the risk for radiation-induced cardiotoxicity (RICT), which is well documented among patients with HD and breast cancer...
December 13, 2017: Journal of Thoracic Oncology
Yen-Han Tseng, Hsiang-Ling Ho, Chiung-Ru Lai, Yung-Hung Luo, Yen-Chiang Tseng, Jacqueline Whang-Peng, Yi-Hsuan Lin, Teh-Ying Chou, Yuh-Min Chen
INTRODUCTION: Weather we could use IHC stain of PD-L1 on cells of pleural effusion to predict immunotherapy treatment response have not been reported. METHODS: We retrospectively enrolled patients who had undergone malignant pleural effusion drainage and had effusion cell block specimens from 2014-2016. IHC staining for PD-L1 was performed with tumor cells, immune cells, and macrophage of all cell block specimens. The immunoactivity was defined as 0 for absence of staining; 1+ for faint; 2+ for moderate; 3+ for intense membranous staining...
December 12, 2017: Journal of Thoracic Oncology
Lars Soraas, Justin Stebbing
Our understanding of the etiology of EGFR mutant lung cancer remains incomplete. One persistent finding in the literature is the geographic variation in the frequency of EGFR mutations in lung adenocarcinoma. We investigated the association between two biomarkers of East Asian ancestry, the genetic polymorphisms EDAR V370A and ABCC11 G180A, and the frequency of EGFR mutations in lung adenocarcinoma patients in a range of countries. The Pearson's linear correlation between the frequency of EGFR mutations and the EDAR polymorphism was 0...
December 12, 2017: Journal of Thoracic Oncology
Keiju Aokage, Tomohiro Miyoshi, Genichiro Ishii, Masahiro Kusumoto, Shogo Nomura, Shinya Katsumata, Keigo Sekihara, Kenta Tane, Masahiro Tsuboi
INTRODUCTION: The aim was to clarify the influence on patient prognosis of ground glass opacity (GGO) component in each new tumor-node-metastasis stage and propose grouping reflecting the prognosis more accurately. METHODS: We examined the data of 1290 patients who underwent lung cancer resection from 2003 to 2011. The demographics and overall survival of patients with adenocarcinoma with and without GGO, squamous cell carcinoma, and the others, were compared according to clinical stage (c-stage) from 0 to IB...
December 12, 2017: Journal of Thoracic Oncology
Friedrich Stiefel, Céline Bourquin
No abstract text is available yet for this article.
December 11, 2017: Journal of Thoracic Oncology
Soon Ho Yoon, Seung Ho Choi, Chang Hyun Kang, Jin Mo Goo
HYPOTHESIS: To investigate the prevalence and characteristics of nodular lesions in the anterior mediastinum that had been incidentally found on screening chest CT in asymptomatic subjects. METHODS: We included 56,358 consecutive participants (mean age, 52.4±10.5 years; male-female, 35,306:21,052) who underwent a baseline low-dose chest CT scan for health checkups from 2006 through 2013. After confirming the presence of anterior mediastinal nodular lesion, their CT findings, confirmatory diagnosis and interval CT scan were reviewed...
December 9, 2017: Journal of Thoracic Oncology
Laura P Stabile, Mariya Farooqui, Beatriz Kanterewicz, Shira Abberbock, Brenda F Kurland, Brenda Diergaarde, Jill M Siegfried
INTRODUCTION: A hormonal role in non-small cell lung cancer (NSCLC) development is well documented. We previously showed that the aromatase inhibitor (AI) anastrozole decreased the development of tobacco carcinogen-induced lung tumors in a murine lung cancer prevention model and that aromatase and estrogen receptor (ER) were expressed in pulmonary inflammatory cells. METHODS: We utilized a tobacco carcinogen-induced lung tumor mouse model [4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)] to determine whether an AI combined with non-steroidal anti-inflammatory drugs (NSAIDs) results in greater lung tumor prevention effects than single agent treatment...
December 9, 2017: Journal of Thoracic Oncology
Daichi Fujimoto, Yuki Sato, Keiichiro Uehara, Kaori Ishida, Junya Fukuoka, Takeshi Morimoto, Hayato Kawachi, Ryobu Mori, Munehiro Ito, Shunsuke Teraoka, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Yukihiro Imai, Keisuke Tomii
INTRODUCTION: Nivolumab has demonstrated efficacy against metastatic non-small cell lung cancer (NSCLC). Four programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) assay systems are available for identification of responders among patients with NSCLC, and these assays show some differing characteristics. Accordingly, in this study, we evaluated the ability of these assays to identify responders to nivolumab therapy. METHODS: We retrospectively analyzed patients with previously treated advanced NSCLC, who received nivolumab between January 2016 and September 2016...
December 9, 2017: Journal of Thoracic Oncology
Julien Faget, Caroline Contat, Nadine Zangger, Solange Peters, Etienne Meylan
HYPOTHESIS: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality. Recent retrospective clinical analyses suggest that blocking the receptor activator of NF-κB (RANK) signaling pathway inhibits the growth of NSCLC and might represent a new treatment strategy. METHODS: RANK and RANKL expression in human lung adenocarcinoma was interrogated from publicly available gene expression datasets. Several genetically engineered mouse models were used to evaluate treatment efficacy of RANK-Fc to block RANKL, with primary tumor growth measured longitudinally using micro-computed tomography...
December 6, 2017: Journal of Thoracic Oncology
Anne S Tsao, Heather Lin, Brett W Carter, J Jack Lee, David Rice, Ara Vaporcyan, Steven Swisher, Reza Mehran, John Heymach, Monique Nilsson, Youhong Fan, Maria Nunez, Lixia Diao, Jing Wang, Junya Fujimoto, Ignacio I Wistuba, Waun Ki Hong
Window-of-opportunity trials in malignant pleural mesothelioma (MPM) are challenging but can yield important translational information about a novel agent. We treated MPM patients (n=24) with 4 weeks of oral dasatinib followed by surgery with or without radiotherapy and then an optional 2 years of maintenance dasatinib. The primary endpoint was biomarker modulation of p-SrcTyr419. For all patients, the median PFS was 7.5 months and OS 19.1 months. No significant responses were seen after 4 weeks of dasatinib therapy, however, modulation of p-SrcTyr419 immunohistochemistry (IHC) scores (median (interquartile range) = 70 (37...
December 4, 2017: Journal of Thoracic Oncology
Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Ohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada, Naoyuki Nogami, Taizo Hirata, Shiro Hinotsu, Shinichi Toyooka, Katsuyuki Kiura
Trastuzumab emtansine (T-DM1), an anti-HER2 antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed non-small-cell lung cancer (NSCLC). with documented HER2-positivity (immunohistochemistry [IHC] 3+, both IHC 2+ and fluorescence in situ hybridization [FISH] +, or exon 20 mutation). This study was terminated early due to limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: age (median: 67 years), sex (male: 47%), performance status (0-1: 80%), and HER2 status (IHC 3+: 33%; IHC 2+/FISH: 20%; mutation: 47%)...
December 4, 2017: Journal of Thoracic Oncology
Sukhmani K Padda, Xiaopan Yao, Alberto Antonicelli, Jonathan W Riess, Yue Shang, Joseph B Shrager, Robert Korst, Frank Detterbeck, James Huang, Bryan M Burt, Heather A Wakelee, Sunil S Badve
INTRODUCTION: Thymic epithelial tumors (TETs) are associated with paraneoplastic autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. METHODS: The International Thymic Malignancy Interest Group (ITMIG) retrospective database was examined to determine (i) baseline and treatment characteristics associated with PN/AI syndromes and (ii) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS)...
November 27, 2017: Journal of Thoracic Oncology
Mian Xie, Xiaojun Wu, Fang Wang, Jinjun Zhang, Xiaosong Ben, Jiexia Zhang, Xiaoxiang Li
No abstract text is available yet for this article.
November 27, 2017: Journal of Thoracic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"